Clinical Trials Logo

Pancreatic Adenocarcinoma clinical trials

View clinical trials related to Pancreatic Adenocarcinoma.

Filter by:

NCT ID: NCT03871790 Completed - Pancreatic Cancer Clinical Trials

Peptide-based Immunization for Colon- and and Pancreas-carcinoma

PICOP-GLOBAL
Start date: April 1, 2019
Phase:
Study type: Observational

An international, multicenter study to identify tumor molecular particularities and neoepitopes among participants with colorectal and pancreatic tumors undergoing surgery.

NCT ID: NCT03745430 Completed - Clinical trials for Pancreatic Adenocarcinoma

RAmucirumab Combined wIth Standard Nab-paclitaxel and Gemcitabine as First-line Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma

RACING
Start date: January 29, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

RACING (RAmucirumab Combined wIth standard Nab-paclitaxel and Gemcitabine as first-line chemotherapy in patients with advanced pancreatic adenocarcinoma) trial is a Greek, investigator-initiated, single-arm, open-label phase Ib-II study. Patients with advanced cytologically or histologically proven pancreatic adenocarcinoma will be treated with a combination of Ramucirumab with Nab-paclitaxel and Gemcitabine (for a maximum of 8 cycles followed by Ramucirumab maintenance) until disease progression or excessive Adverse Events (AEs) or Investigator's decision or patient's refusal of further treatment or death, whichever comes first.

NCT ID: NCT03665441 Completed - Clinical trials for Pancreatic Adenocarcinoma

Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC

Trybeca-1
Start date: September 15, 2018
Phase: Phase 3
Study type: Interventional

This is an open-label, multicenter, randomized, Phase 3 study in patients with ductal adenocarcinoma of the pancreas who have failed only one prior line of systemic anti-cancer therapy for advanced pancreatic cancer and have measurable disease.

NCT ID: NCT03578445 Completed - Clinical trials for Pancreatic Adenocarcinoma

Utility of EUS-guided Microbiopsies in Pancreatic Cystic Lesions

Start date: February 1, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to determine clinical impact of EUS-guided microbiopsy procedure and supplementary molecular analyses compared to standard diagnostic workup of pancreatic cysts. The hypothesis is that a combination of previously mentioned modalities may change the management of some pancreatic cystic lesions, increase the diagnostic accuracy and optimize the discrimination between high- and low-risk pancreatic cysts.

NCT ID: NCT03567863 Completed - Pancreas Cancer Clinical Trials

Study Comparing Pancreatic EUS-FNB With the 20-gauge Procore® and the 22-gauge Acquire® Needles

HISTOPAN
Start date: June 24, 2018
Phase: N/A
Study type: Interventional

Multicenter randomized prospective study Criteria for inclusion: Patients admitted for EUS-FNB of a pancreatic mass Goals of the study: To compare the results of blinded punctures for suspicion of pancreatic tumor performed under endoscopic ultrasound in our center (Digestive Endoscopy Unit of the Digestive Pole Paris Bercy, PDPB), in terms of diagnosis and quality of histopathological material obtained with the help of 20G Procore, Cook and 22G Acquire needles, Boston Scientific. Main criterion: - Biopsy core length of target tissue obtained by needle pass Number of patients: 60 patients Duration of the study: 1 year

NCT ID: NCT03559348 Completed - Clinical trials for Pancreatic Adenocarcinoma

Locally Advanced or Metastatic Pancreatic Adenocarcinoma

Start date: April 3, 2018
Phase: Phase 2
Study type: Interventional

Multiple centers, uncontrolled, open-label, non-randomized single-arm study

NCT ID: NCT03415854 Completed - Pancreatic Cancer Clinical Trials

Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)

NABPLAGEMD
Start date: January 31, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if the combination of paclitaxel protein bound, gemcitabine, cisplatin, paricalcitol are effective in individuals with previously untreated metastatic pancreatic cancer.

NCT ID: NCT03373188 Completed - Clinical trials for Pancreatic Adenocarcinoma

VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer

Start date: December 15, 2017
Phase: Phase 1
Study type: Interventional

This randomized phase I trial studies how well anti-semaphorin 4D (anti-SEMA4D) monoclonal antibody VX15/2503 with or without ipilimumab or nivolumab work in treating patients with stage I-III pancreatic cancer that can be removed by surgery or stage IV colorectal cancer that has spread to the liver and can be removed by surgery. Monoclonal antibodies, such as anti-SEMA4D monoclonal antibody VX15/2503, ipilimumab, and nivolumab, may interfere with the ability of tumor cells to grow and spread.

NCT ID: NCT03329950 Completed - Breast Cancer Clinical Trials

A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies

Start date: December 1, 2017
Phase: Phase 1
Study type: Interventional

This is a study to determine the maximum tolerated dose (MTD) for CDX-1140 (CD40 antibody), either alone or in combination with CDX-301 (FLT3L), pembrolizumab, or chemotherapy and to further evaluate its tolerability and efficacy in expansion cohorts once the MTD is determined.

NCT ID: NCT03318497 Completed - Clinical trials for Pancreatic Adenocarcinoma

Role of Interim 18F-FLT PET/CT for Outcome Prediction in Pancreatic Adenocarcinoma

Start date: December 11, 2017
Phase: Phase 2
Study type: Interventional

To assess if percentage change in 18F-FLT PET/CT quantitative parameters (SUV max, or SUV peak or proliferative tumor volume) after 2 cycles of neoadjuvant chemotherapy can predict overall survival at 1 and 2 years and progression free survival at 6 months and 1 year in patients with borderline resectable or locally advanced, pancreatic adenocarcinoma.